Sorafenib is a dual inhibitor of KIT and RAF and since, GIST-T1/670 is still dependent on KIT, inhibition of both KIT and downstream MAPK pathway appeared to be cytotoxic for this cell line. Here, RAF1 is linked to gastrointestinal stromal tumor.